aTyr Pharma gets FDA Fast Track for efzofitimod in pulmonary sarcoidosis

aTYR PHARMA INC

FDA granted Fast Track designation on August 9, 2022 for lead candidate efzofitimod.
Fast Track aims to expedite development and review; may allow rolling submission.
Pulmonary sarcoidosis is a major interstitial lung disease with no approved therapies.
Efzofitimod is a novel immunomodulator targeting neuropilin-2; Phase 3 trial ongoing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.